Showing results (1-10 of 277) with videos related to
Sort By:
Pageof 28
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2015
Advances in clinical trials for movement disordersKarl Kieburtz, C Warren OlanowMovement Disorders : Official Journal of the Movement Disorder Society|September 15, 2010
Defining disease-modifying therapies for PD--a road map for moving forwardC Warren Olanow, Karl KieburtzThe Mount Sinai Journal of Medicine, New York|May 23, 2007
Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapyKarl Kieburtz, C Warren OlanowMovement Disorders : Official Journal of the Movement Disorder Society|May 9, 2018
Huntington's disease: Current and future therapeutic prospectsKarl Kieburtz, Ralf Reilmann, C Warren OlanowMovement Disorders : Official Journal of the Movement Disorder Society|June 1, 2011
Milestones in movement disorders clinical trials: advances and landmark studiesC Warren Olanow, Kathryn B Wunderle, Karl KieburtzMovement Disorders : Official Journal of the Movement Disorder Society|October 7, 2020
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another PandemicKarl Kieburtz, Russell Katz, Andrew McGarry, et al.Annals of Neurology|January 8, 2009
Why have we failed to achieve neuroprotection in Parkinson's disease?C Warren Olanow, Karl Kieburtz, Anthony H V SchapiraMovement Disorders : Official Journal of the Movement Disorder Society|April 7, 2020
Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease PatientsC Warren Olanow, David G Standaert, Karl Kieburtz, et al.Journal of Huntington'S Disease|November 9, 2020
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD StudyAndrew McGarry, Mika Leinonen, Karl Kieburtz, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 3, 2025
A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's diseaseBradley T Wyman, Dan Adams, Suzanne Hendrix, et al.Pageof 28